Program
HS-20137
A development code.
Its studies are mostly in Psoriasis, led by Hansoh Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 22 open or running | phase 3since Feb 7, 2025 | Feb 7, 2025 | Mar 1, 2027phase 2 · NCT07879885 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 7, 2025First study: phase 3 study in Moderate-to-severe Plaque PsoriasisFirst studyNCT06844799 · 720 planned
- Oct 11, 2026Phase 2 study in Moderate-to-severe Plaque PsoriasisNCT07879885 · 390 planned · China
Ahead
- Mar 1, 2027Primary completion: phase 2 study in Moderate-to-severe Plaque PsoriasisNCT07879885
- Mar 31, 2027Primary completion: phase 3 study in Moderate-to-severe Plaque PsoriasisNCT06844799
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07879885Moderate-to-severe Plaque Psoriasis · China | 2 | Recruiting | Mar 1, 2027 | 390 |
| NCT06844799Moderate-to-severe Plaque Psoriasis | 3 | Not yet recruiting | Mar 31, 2027 | 720 |
How it is read
Names in the registry
- “HS-20137”, 2 entries
Codes read as this program: HS20137.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.